An integrated science-based approach to drug development.

[1]  P. Parren,et al.  Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. , 2008, Blood.

[2]  P. Parren,et al.  Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. , 2008, Cancer research.

[3]  Ming Li,et al.  Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms* , 2008, Journal of Biological Chemistry.

[4]  Robert M. Anthony,et al.  Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc , 2008, Science.

[5]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Salfeld,et al.  Isotype selection in antibody engineering , 2007, Nature Biotechnology.

[8]  G. A. Lazar,et al.  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.

[9]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[10]  Yoshiki Yamaguchi,et al.  Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. , 2007, Journal of molecular biology.

[11]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[12]  Max Wolf,et al.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.

[13]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.